Nonetheless, clinical trials have demonstrated that secukinumab, an IL-17A inhibitor that is effective in treating psoriasis and PsA, is associated with the onset or exacerbation of IBD, including Crohn’s disease and ulcerative colitis. Here, IL17A is linked to Crohn disease.